Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Texas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Texas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 45 Texas 33 Florida 32 New York 31 Massachusetts 25
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
PAQ Therapeutics, Inc.2 ImmunoGenesis1 Klus Pharma Inc.1 Teligene US1 Alyssum Therapeutics1
State
California45 Texas33 Florida32 New York31 Massachusetts25
All 43 states
Target enrolment
to

Trials with a site in Texas

33 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Gilead Sciences
Phase 1
302
Michigan, Texas
2026-07-17
Recruiting
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1
40
California, Texas, Utah
2026-04-13
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
210
Massachusetts, Texas, Utah, Virginia
2025-11-21
Recruiting
ITM Solucin GmbH
Phase 1
20
California, Ohio, Pennsylvania, Texas
2025-09-26
Recruiting
STORM Therapeutics LTD
Phase 1/2
107
California, Florida, Massachusetts, Michigan, New York, Ohio, Texas, Virginia
2025-05-05
Recruiting
PAQ Therapeutics, Inc.
Phase 1
300
California, Massachusetts, Michigan, Tennessee, Texas, Utah, Virginia
2024-12-19
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
120
California, Colorado, Florida, Illinois, Ohio, Tennessee, Texas, Washington
2024-08-14
Recruiting
Step Pharma, SAS
Phase 1
70
Florida, Texas
2024-08-02
Recruiting
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
NCT06452160Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
BridGene Biosciences Inc.
Phase 1
103
Texas
2024-06-27
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Recruiting
Alyssum Therapeutics
Phase 1/2
100
Arizona, California, New York, Oregon, Texas
2024-02-13
Active, closed
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
NCT06160752Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Tyra Biosciences, Inc
Phase 1
40
California, Massachusetts, Ohio, Texas
2023-11-22
Recruiting
Qualigen Theraputics, Inc.
Phase 1
54
Arizona, Connecticut, Michigan, Texas
2023-11-01
Recruiting
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
Recruiting
ImmunoGenesis
Phase 1
105
Arizona, California, Florida, Kentucky, Louisiana, Missouri, Pennsylvania, Texas
2023-09-07
Recruiting
Chugai Pharmaceutical
Phase 1
209
Pennsylvania, Rhode Island, Tennessee, Texas, Virginia
2023-05-24
Active, closed
A2 Biotherapeutics Inc.
Phase 1/2
160
Arizona, California, Florida, Minnesota, Missouri, New York, Texas
2023-04-28
Active, closed
DEKA Biosciences
Phase 1
39
California, New York, Oklahoma, Texas, Virginia
2023-04-03
Recruiting
Teligene US
Phase 2
60
California, Texas
2023-03-16
Recruiting
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
NCT05784688Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
DrugsTU2218·Keytruda·Pembrolizumab
TiumBio Co., Ltd.
Phase 1/2
140
Texas, Washington
2023-03-10
Active, closed
Klus Pharma Inc.
Phase 2
240
Indiana, Kentucky, Maryland, Minnesota, New York, Texas, Virginia
2023-01-17
Recruiting
Sanofi
Phase 1/2
542
Delaware, Iowa, Kansas, Michigan, New Jersey, New York, Rhode Island, Texas
2022-11-29
Recruiting
Impact Therapeutics, Inc.
Phase 1/2
61
New Jersey, New York, South Carolina, Texas
2022-02-11
Active, closed
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
NCT05199272Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer
23andMe, Inc.
Phase 1/2
141
California, Georgia, Michigan, New York, Oregon, Tennessee, Texas, Virginia
2021-12-29
Active, closed
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
HUYABIO International, LLC.
Phase 1
42
California, Florida, Ohio, Texas, Virginia
2021-12-13
Active, closed
TH1902 in Patients With Advanced Solid Tumors
NCT04706962Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
Theratechnologies
Phase 1
70
Michigan, Pennsylvania, Texas
2021-03-04
Recruiting
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
NCT04516447Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
DrugsAzenosertib·Pegylated liposomal doxorubicin·Gemcitabine·Paclitaxel
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1
172
Colorado, Massachusetts, Missouri, New York, North Carolina, Rhode Island, Tennessee, Texas
2020-10-26
Recruiting
ImmVira Pharma Co. Ltd
Phase 1/2
30
Arizona, Massachusetts, Pennsylvania, Texas, Virginia
2020-09-17
Active, closed
Idera Pharmaceuticals, Inc.
Phase 2
30
Arizona, California, Texas
2019-10-29
Recruiting
Trial of DFP-14927 in Advanced Solid Tumors
NCT03943004Solid Tumor, Cancer
Delta-Fly Pharma, Inc.
Phase 1
30
California, Texas
2019-09-30
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Arizona, Maryland, Ohio, Texas
2018-01-26
Active, closed
Eli Lilly and Company
Phase 1
223
Kentucky, New York, Texas
2016-11-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
370
Colorado, Illinois, Massachusetts, New York, North Dakota, South Dakota, Texas
2015-03-19
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/state/texas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies with a site in Texas that also match the filters currently applied.

How many clinical trials are recruiting in Texas?

23 of the 33 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Texas), 33 studies
PhaseStudiesRecruitingShare
Phase 1181354.5%
Phase 1/211833.3%
Phase 2319.1%
Phase 4113%

Most active sponsors

Lead sponsors with the most studies (Texas)
Lead sponsorStudiesRecruiting
PAQ Therapeutics, Inc.22
23andMe, Inc.10
A2 Biotherapeutics Inc.10
Affini-T Therapeutics, Inc.10
Alyssum Therapeutics11
BeOne Medicines11
BridGene Biosciences Inc.11
Chugai Pharmaceutical11
DEKA Biosciences10
Delta-Fly Pharma, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.